Sources of variability in ketoconazole inhibition of human cytochrome P450 3A in vitro

Xenobiotica

Volumn 40, Issue 10, 2010, Pages 713-720

  Greenblatt, David J ^a   Venkatakrishnan, Karthik ^b   Harmatz, Jerold S ^a   Parent, Sarah J ^a   Von Moltke, Lisa L ^c  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MILLENNIUM PHARMACEUTICALS INC   (United States)

^c GENZYME CORPORATION   (United States)

Author keywords

cytochrome P450 3A; drug interactions; Ketoconazole; metabolic inhibition

Indexed keywords

CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; KETOCONAZOLE; MIDAZOLAM;

DRUG CLEARANCE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; ENZYME INHIBITION; HUMAN; HYDROXYLATION; IC 50; IN VITRO STUDY; INCUBATION TIME; LIVER MICROSOME; REVIEW;

ANTIFUNGAL AGENTS; CYTOCHROME P-450 CYP3A; HUMANS; KETOCONAZOLE; PROTEIN ISOFORMS; SUBSTRATE SPECIFICITY;

EID: 77956592952     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2010.506224     Document Type: Review

References (79)

1. Allqvist A, Miura J, Bertilsson L, Mirghani RA. (2007). Inhibition of CYP3A4 and CYP3A5 catalyzed metabolism of alprazolam and quinine by ketoconazole as racemate and four diferent enanti-omers. Eur J Clin Pharmacol 63:173-179.
2. Bachmann KA. (2006). Inhibition constants, inhibitor concentrations and the prediction of inhibitory drug drug interactions: pitfalls, progress and promise. Curr Drug Metab 7:1-14.
3. Back DJ, Tjia J F. (1991). Comparative efects of the antimycotic drugs ketoconazole, fuconazole, itraconazole and terbinafne on the metabolism of cyclosporin by human liver microsomes. Br J Clin Pharmacol 32:624-626.
4. Baune B, Furlan V, Taburet AM, Farinotti R. (1999). Efect of selected antimalarial drugs and inhibitors of cytochrome P-450 3A4 on halofantrine metabolism by human liver microsomes. Drug Metab Dispos 27:565-568.
5. Bourrié M, Meunier V, Berger Y, Fabre G. (1996). Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J Pharmacol Exp Ter 277:321-332.
6. Christians U, Schmidt G, Bader A, Lampen A, Schottmann R, Linck A, Sewing K F. (1996). Identifcation of drugs inhibiting the in vitro metabolism of tacrolimus by human liver microsomes. Br J Clin Pharmacol 41:187-190.
7. Cook CS, Berry LM, Burton E. (2004). Prediction of in vivo drug interactions with eplerenone in man from in vitro metabolic inhibition data. Xenobiotica 34:215-228.
8. Desta Z, Soukhova N, Mahal SK, Flockhart DA. (2000) Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies. Drug Metab Dispos 28:789-800.
9. Emoto C, Murase S, Sawada Y, Jones BC, Iwasaki K. (2003).In vitro inhibitory efect of 1-aminobenzotriazole on drug oxidations catalyzed by human cytochrome P450 enzymes: a comparison with SKF-525A and ketoconazole. Drug Metab Pharmacokinet 18:287-295.
10. Fayer JL, Petullo DM, Ring BJ, Wrighton SA, Ruterbories KJ. (2002). A novel testosterone 6 beta-hydroxylase activity assay for the study of CYP3A-mediated metabolism, inhibition, and induction in vitro. J Pharmacol Toxicol Methods 46:117-123.
11. Furuta S, Kamada E, Omata T, Sugimoto T, Kawabata Y, Yonezawa K, Wu XC, Kurimoto T. (2004). Drug-drug interactions of Z-338, a novel gastroprokinetic agent, with terfenadine, comparison with cisapride, and involvement of UGT1A9 and 1A8 in the human metabolism of Z-338. Eur J Pharmacol 497:223-231.
12. Galetin A, Clarke SE, Houston JB. (2002). Quinidine and haloperidol as modifers of CYP3A4 activity: multisite kinetic model approach. Drug Metab Dispos 30:1512-1522.
13. Galetin A, Clarke SE, Houston JB. (2003). Multisite kinetic analysis of interactions between prototypical CYP3A4 subgroup substrates: midazolam, testosterone, and nifedipine. Drug Metab Dispos 31:1108-1116.
14. Galetin A, Ito K, Hallifax D, Houston JB. (2005). CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions. J Pharmacol Exp Ter 314:180-190.
15. Gascon MP, Dayer P. (1991). In vitro forecasting of drugs which may interfere with the biotransformation of midazolam. Eur J Clin Pharmacol 41:573-578.
16. Gentile DM, Tomlinson ES, Maggs JL, Park BK, Back DJ. (1996). Dexamethasone metabolism by human liver in vitro. Metabolite identifcation and inhibition of 6-hydroxylation. J Pharmacol Exp Ter 277:105-112.
17. Ghosal A, Chowdhury SK, Tong W, Hapangama N, Yuan Y, Su AD, Zbaida S. (2006). Identifcation of human liver cytochrome P450 enzymes responsible for the metabolism of lonafarnib (Sarasar). Drug Metab Dispos 34:628-635.
18. Gibbs MA, Kunze KL, Howald WN, Tummel KE. (1999a). Efect of inhibitor depletion on inhibitory potency: tight binding inhibition of CYP3A by clotrimazole. Drug Metab Dispos 27:596-599.
19. Gibbs MA, Tummel KE, Shen DD, Kunze KL. (1999b). Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression. Drug Metab Dispos 27:180-187.
20. Grace JM, Skanchy DJ, Aguilar AJ. (1999). Metabolism of artelinic acid to dihydroqinqhaosu by human liver cytochrome P4503A. Xenobiotica 29:703-717.
21. Greenblatt DJ, von Moltke LL. (2010). Clinical studies of drug-drug interactions: design and interpretation. In: Pang KS, Rodrigues AD, Peter RM, eds. Enzyme and transporter-based drug-drug interactions: progress and future challenges. New York: Springer, p. 625-649.
22. Greenblatt DJ, He P, von Moltke LL, Court MH. (2008). Te CYP3 family. In: Ioannides C, ed. Cytochrome p450: role in the metabolism and toxicology of drugs and other xenobiotics. Cambridge (UK): Royal Society of Chemistry, p. 354-383.
23. Hirota N, Ito K, Iwatsubo T, Green CE, Tyson CA, Shimada N, Suzuki H, Sugiyama Y. (2001). In vitro/in vivo scaling of alprazolam metabolism by CYP3A4 and CYP3A5 in humans. Biopharm Drug Dispos 22:53-71.
24. Huang SM, Temple R, Trockmorton DC, Lesko LJ. (2007). Drug interaction studies: study design, data analysis, and implications for dosing and labeling. Clin Pharmacol Ter 81:298-304.
25. Isoherranen N, Ludington SR, Givens RC, Lamba JK, Pusek SN, Dees EC, Blough DK, Iwanaga K, Hawke RL, Schuetz EG, Watkins PB, Tummel KE, Paine MF. (2008). Te infuence of CYP3A5 expression on the extent of hepatic CYP3A inhibition is substrate-dependent: an in vitro-in vivo evaluation. Drug Metab Dispos 36:146-154.
26. Ito K, Brown HS, Houston JB. (2004). Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. Br J Clin Pharmacol 57:473-486.
27. Iwata H, Tezuka Y, Kadota S, Hiratsuka A, Watabe T. (2004). Identifcation and characterization of potent CYP3A4 inhibitors in Schisandra fruit extract. Drug Metab Dispos 32:1351-1358.
28. Jacobsen W, Kirchner G, Hallensleben K, Mancinelli L, Deters M, Hackbarth I, Benet LZ, Sewing KF, Christians U. (1999). Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3- methylglutaryl-CoA reduct-ase inhibitors lovastatin and pravastatin in the liver. Drug Metab Dispos 27:173-179.
29. Jurima-Romet M, Crawford K, Cyr T, Inaba T. (1994). Terfenadine metabolism in human liver: in vitro inhibition by macrolide antibiotics and azole antifungals. Drug Metabolism and Disposition 22:849-857.
30. Kenworthy KE, Bloomer JC, Clarke SE, Houston JB. (1999). CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. Br J Clin Pharmacol 48:716-727.
31. Kumar GN, Dykstra J, Roberts EM, Jayanti VK, Hickman D, Uchic J, Yao Y, Surber B, Tomas S, Granneman GR. (1999). Potent inhibition of the cytochrome P-450 3A-mediated human liver micro-somal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction. Drug Metab Dispos 27:902-908.
32. Lalovic B, Phillips B, Risler LL, Howald W, Shen DD. (2004). Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos 32:447-454.
33. Lampen A, Christians U, Bader A, Hackbarth I, Sewing KF. (1996). Drug interactions and interindividual variability of ciclosporin metabolism in the small intestine. Pharmacology 52:159-168.
34. Lampen A, Christians U, Guengerich FP, Watkins PB, Kolars JC, Bader A, Gonschior AK, Dralle H, Hackbarth I, Sewing K F. (1995). Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindi-vidual variability. Drug Metab Dispos 23:1315-1324.
35. Lampen A, Zhang Y, Hackbarth I, Benet LZ, Sewing KF, Christians U. (1998). Metabolism and transport of the macrolide immunosup-pressant sirolimus in the small intestine. J Pharmacol Exp Ter 285:1104-1112.
36. Li XQ, Andersson TB, Ahlström M, Weidolf L. (2004). Comparison of inhibitory efects of the proton pump-inhibiting drugs omepra-zole, esomeprazole, lansoprazole, pantoprazole, and rabepra-zole on human cytochrome P450 activities. Drug Metab Dispos 32:821-827.
37. Lillibridge JH, Liang BH, Kerr BM, Webber S, Quart B, Shetty BV, Lee CA. (1998). Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immu-nodefciency virus-protease inhibitor nelfnavir mesylate. Drug Metab Dispos 26:609-616.
38. Lin CC, Fang C, Benetton S, Xu GF, Yeh LT. (2006). Metabolic activation of pradefovir by CYP3A4 and its potential as an inhibitor or inducer. Antimicrob Agents Chemother 50:2926-2931.
39. Liu XQ, Ren YL, Qian ZY, Wang GJ. (2000). Enzyme kinetics and inhibition of nimodipine metabolism in human liver microsomes. Acta Pharmacol Sin 21:690-694.
40. Liu XQ, Zhao Y, Li D, Qian ZY, Wang GJ. (2003). Metabolism and metabolic inhibition of cilnidipine in human liver microsomes. Acta Pharmacol Sin 24:263-268.
41. Marre F, Sanderink GJ, de Sousa G, Gaillard C, Martinet M, Rahmani R. (1996). Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. Cancer Res 56:1296-1302.
42. Martínez C, García-Martín E, Pizarro RM, García-Gamito FJ, Agúndez JA. (2002). Expression of paclitaxel-inactivating CYP3A activity in human colorectal cancer: implications for drug therapy. Br J Cancer 87:681-686.
43. Maurice M, Pichard L, Daujat M, Fabre I, Joyeux H, Domergue J, Maurel P. (1992). Efects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. FASEB J 6:752-758.
44. Nielsen TL, Rasmussen BB, Flinois JP, Beaune P, Brosen K. (1999). In vitro metabolism of quinidine: the (3S)-3-hydroxylation of quinidine is a specifc marker reaction for cytochrome P-4503A4 activity in human liver microsomes. J Pharmacol Exp Ter 289:31-37.
45. Niwa T, Murayama N, Emoto C, Yamazaki H. (2008). Comparison of kinetic parameters for drug oxidation rates and substrate inhibition potential mediated by cytochrome P450 3A4 and 3A5. Curr Drug Metab 9:20-33.
46. Obach RS, Walsky RL, Venkatakrishnan K, Houston JB, Tremaine LM. (2005). In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: qualitative relationships, quantitative predictions, and the rank-order approach. Clin Pharmacol Ter 78:582-592.
47. Omar G, Whiting PH, Hawksworth GM, Humphrey MJ, Burke MD. (1997). Ketoconazole and fuconazole inhibition of the metabolism of cyclosporin A by human liver in vitro. Ter Drug Monit 19:436-445.
48. Pan L P, Wijnant P, De Vriendt C, Rosseel MT, Belpaire FM. (1997). Characterization of the cytochrome P450 isoenzymes involved in the in vitro N-dealkylation of haloperidol. Br J Clin Pharmacol 44:557-564.
49. Patki KC, Von Moltke LL, Greenblatt DJ. (2003). In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. Drug Metab Dispos 31:938-944.
50. Pelkonen O, Turpeinen M, Hakkola J, Honkakoski P, Hukkanen J, Raunio H. (2008). Inhibition and induction of human cytochrome P450 enzymes: current status. Arch Toxicol 82:667-715.
51. Perlof MD, von Moltke LL, Court MH, Kotegawa T, Shader RI, Greenblatt DJ. (2000). Midazolam and triazolam biotransfor-mation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms. J Pharmacol Exp Ter 292:618-628.
52. Pichard L, Fabre I, Fabre G, Domergue J, Saint Aubert B, Mourad G, Maurel P. (1990). Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab Dispos 18:595-606.
53. Prueksaritanont T, Gorham LM, Ma B, Liu L, Yu X, Zhao JJ, Slaughter DE, Arison BH, Vyas KP. (1997). In vitro metabolism of simvastatin in humans [SBT]identifcation of metabolizing enzymes and efect of the drug on hepatic P450s. Drug Metab Dispos 25:1191-1199.
54. Satoh T, Munakata H, Fujita K, Itoh S, Itoh S, Kamataki T, Yoshizawa I. (2003). Studies on the interactions between drug and estrogen. II. On the inhibitory efect of 29 drugs reported to induce gyneco-mastia on the oxidation of estradiol at C-2 or C-17. Biol Pharm Bull 26:695-700.
55. Sekiguchi N, Higashida A, Kato M, Nabuchi Y, Mitsui T, Takanashi K, Aso Y, Ishigai M. (2009). Prediction of drug-drug interactions based on time-dependent inhibition from high throughput screening of cytochrome P450 3A4 inhibition. Drug Metab Pharmacokinet 24:500-510.
56. Senda C, Kishimoto W, Sakai K, Nagakura A, Igarashi T. (1997). Identifcation of human cytochrome P450 isoforms involved in the metabolism of brotizolam. Xenobiotica 27:913-922.
57. Soars MG, Grime K, Riley RJ. (2006). Comparative analysis of substrate and inhibitor interactions with CYP3A4 and CYP3A5. Xenobiotica 36:287-299.
58. Stresser DM, Blanchard AP, Turner SD, Erve JC, Dandeneau AA, Miller VP, Crespi CL. (2000). Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fuorometric substrates. Drug Metab Dispos 28:1440-1448.
59. Tummel KE, Wilkinson GR. (1998). In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 38:389-430.
60. Tran TH, von Moltke LL, Venkatakrishnan K, Granda BW, Gibbs MA, Obach RS, Harmatz JS, Greenblatt DJ. (2002). Microsomal protein concentration modifes the apparent inhibitory potency of CYP3A inhibitors. Drug Metab Dispos 30:1441-1445.
61. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. (2000). Efects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 38:111-180.
62. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. (2001). Human drug metabolism and the cytochromes P450: application and relevance of in vitro models. J Clin Pharmacol 41:1149-1179.
63. Venkatakrishnan K, von Moltke LL, Obach RS, Greenblatt DJ. (2003). Drug metabolism and drug interactions: application and clinical value of in vitro models. Curr Drug Metab 4:423-459.
64. Volak LP, Greenblatt DJ, von Moltke LL. (2008). In vitro approaches to anticipating clinical drug interactions. In: Li AP, ed. Drug-drug interactions in pharmaceutical development. Hoboken, NJ: John Wiley & Sons, p. 75-93.
65. Von Moltke LL, Durol AL, Duan SX, Greenblatt DJ. (2000). Potent mechanism-based inhibition of human CYP3A in vitro by ampre-navir and ritonavir: comparison with ketoconazole. Eur J Clin Pharmacol 56:259-261.
66. Von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Harmatz JS, Shader RI. (1994a). Inhibitors of alprazolam metabolism in vitro: efect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. Br J Clin Pharmacol 38:23-31.
67. Von Moltke LL, Greenblatt DJ, Duan SX, Harmatz JS, Shader RI. (1994b). In vitro prediction of the terfenadine-ketoconazole phar-macokinetic interaction. J Clin Pharmacol 34:1222-1227.
68. Von Moltke LL, Greenblatt DJ, Harmatz JS, Duan SX, Harrel LM, Cotreau-Bibbo MM, Pritchard GA, Wright CE, Shader RI. (1996a). Triazolam biotransformation by human liver microsomes in vitro: efects of metabolic inhibitors and clinical confrmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ter 276:370-379.
69. Von Moltke LL, Greenblatt DJ, Schmider J, Duan SX, Wright CE, Harmatz JS, Shader RI. (1996b). Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fuoxetine, nor-fuoxetine, and by azole antifungal agents. J Clin Pharmacol 36:783-791.
70. Von Moltke LL, Greenblatt DJ, Duan SX, Harmatz JS, Wright CE, Shader RI. (1996c). Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo. J Clin Psychopharmacol 16:104-112.
71. Wandel C, Kim RB, Guengerich FP, Wood AJ. (2000). Mibefradil is a P-glycoprotein substrate and a potent inhibitor of both P-glycoprotein and CYP3A in vitro. Drug Metab Dispos 28:895-898.
72. Wang JS, Wen X, Backman JT, Taavitsainen P, Neuvonen PJ, Kivistö KT. (1999). Midazolam alpha-hydroxylation by human liver micro-somes in vitro: inhibition by calcium channel blockers, itracona-zole and ketoconazole. Pharmacol Toxicol 85:157-161.
73. Ward BA, Morocho A, Kandil A, Galinsky RE, Flockhart DA, Desta Z. (2004). Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro. Br J Clin Pharmacol 58:277-287.
74. Weemhof JL, von Moltke LL, Richert C, Hesse LM, Harmatz JS, Greenblatt DJ. (2003). Apparent mechanism-based inhibition of human CYP3A in vitro by lopinavir. J Pharm Pharmacol 55:381-386.
75. Wrighton SA, Ring BJ. (1994). Inhibition of human CYP3A catalyzed 1'-hydroxy midazolam formation by ketoconazole, nifed-ipine, erythromycin, cimetidine, and nizatidine. Pharm Res 11:921-924.
76. Zalma A, von Moltke LL, Granda BW, Harmatz JS, Shader RI, Greenblatt DJ. (2000). In vitro metabolism of trazodone by CYP3A: inhibition by ketoconazole and human immunodefciency viral protease inhibitors. Biol Psychiatry 47:655-661.
77. Zhao XJ, Ishizaki T. (1999). A further interaction study of quinine with clinically important drugs by human liver microsomes: determinations of inhibition constant (Ki) and type of inhibition. Eur J Drug Metab Pharmacokinet 24:272-278.
78. Zhou SF. (2008). Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab 9:310-322.
79. Zhou-Pan XR, Sérée E, Zhou XJ, Placidi M, Maurel P, Barra Y, Rahmani R. (1993). Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions. Cancer Res 53:5121-5126.